药物干预增生性瘢痕的研究进展

史亮亮; 刘名倬; 江政英; 虞小亭; 李嘉琪; 郭光华

doi:10.3760/cma.j.cn501120-20211118-00388

药物干预增生性瘢痕的研究进展

doi: 10.3760/cma.j.cn501120-20211118-00388

南昌大学第一附属医院烧伤整形与创面修复医学中心，南昌　　330006

基金项目:

国家自然科学基金地区科学基金项目 82160376, 81960352

江西省科学技术厅重点研发计划项目 20171ACG70004

江西省青年科学基金资助项目 20192BAB215029

详细信息

通讯作者:
郭光华，Email：guogh2000@hotmail.com

计量
- 文章访问数: 312
- HTML全文浏览量: 29
- PDF下载量: 48
- 被引次数: 0
出版历程
- 收稿日期: 2021-11-18

Research advances on pharmacological interventions for hypertrophic scar

Medical Center of Burn Plastic and Wound Repair, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Funds:

Regional Science Fund Project of National Natural Science Foundation of China 82160376, 81960352

Key Research and Development Plan of Science and Technology Department of Jiangxi Province of China 20171ACG70004

Youth Science Foundation of Jiangxi Province of China 20192BAB215029

More Information

Corresponding author: Guo Guanghua, Email: guogh2000@hotmail.com

摘要

摘要: 增生性瘢痕是皮肤深层损伤后出现的纤维异常增生性疾病，不但影响美观与功能，还会对患者心理产生不良影响。然而增生性瘢痕的发生机制尚未被完全阐明，其临床治疗复杂且复发率高，尚无确切的根治方法。基于分子靶点的干预，将可能是未来预防和治疗增生性瘢痕的方向。该文结合国内外相关基础研究与临床研究进展，围绕一般药物、细胞因子、免疫调节剂、中药提取物、外泌体、纳米材料等药物靶向干预增生性瘢痕的具体作用和机制进行综述。
- 瘢痕 /
- 药物疗法 /
- 二甲双胍 /
- 肉毒杆菌毒素类，A型 /
- 外泌体
Abstract: Hypertrophic scar is an abnormal fibrous proliferative disease that occurs after deep cutaneous injury, which not only affects aesthetics and function but also has negative psychological effects on the patients. However, the mechanism of hypertrophic scar formation has not been fully elucidated, and its clinical treatment is complex with a high rate of recurrence and no radicle cure. Intervention based on molecular targets will likely be the future direction for the prevention and treatment of hypertrophic scar. In this article, we review the specific roles and mechanisms of drug-targeted interventions in hypertrophic scar formation, including general drugs, cytokines, immunomodulators, herbal extracts, exosomes, and nanomaterials, in the context of advances in both basic and clinical research at home and abroad.
- Cicatrix /
- Drug therapy /
- Metformin /
- Botulinum toxins, type A /
- Exosomes
所有作者均声明不存在利益冲突

HTML全文

参考文献(43)

[1]	GovermanJ, HeW, MartelloG, et al. The presence of scarring and associated morbidity in the Burn Model System national database[J]. Ann Plast Surg,2019,82(3 Suppl 2):S162-168. DOI: 10.1097/SAP.0000000000001826.
[2]	KhalidFA, MehroseMY, SaleemM, et al. Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: randomised control trial[J]. Burns,2019,45(1):69-75. DOI: 10.1016/j.burns.2018.08.011.
[3]	MaoXH,WoY,HeR,et al.Preparation and characterization of different sizes of ethosomes encapsulated with 5-fluorouracil and its experimental study of permeability in hypertrophic scar[J].J Nanosci Nanotechnol,2010,10(7):4178-4183.DOI: 10.1166/jnn.2010.2207.
[4]	TawfikAA, FathyM, BadawiA, et al. Topical 5 fluorouracil cream vs combined 5 fluorouracil and fractional erbium YAG laser for treatment of severe hypertrophic scars[J]. Clin Cosmet Investig Dermatol,2019,12:173-180. DOI: 10.2147/CCID.S191137.
[5]	KimWI, KimS, ChoSW, et al. The efficacy of bleomycin for treating keloid and hypertrophic scar: a systematic review and meta-analysis[J]. J Cosmet Dermatol,2020,19(12):3357-3366. DOI: 10.1111/jocd.13390.
[6]	XieY, WangH, MaoJZ, et al. Enhanced in vitro efficacy for inhibiting hypertrophic scar by bleomycin-loaded dissolvinghyaluronic acid microneedles[J]. J Mater Chem B,2019,7(42):6604-6611. DOI: 10.1039/c9tb01449g.
[7]	胡大海,汤朝武,陈璧,等.三苯氧胺抑制瘢痕成纤维细胞DNA及胶原合成[J].第四军医大学学报,2000,21(12):1527-1529.DOI: 10.3321/j.issn:1000-2790.2000.12.030.
[8]	MehrvarzS, EbrahimiA, SahraeiH, et al. Effects of topical tamoxifen on wound healing of burned skin in rats[J]. Arch Plast Surg,2017,44(5):378-383. DOI: 10.5999/aps.2017.44.5.378.
[9]	SunY, GeYB, FuYX, et al. Mitomycin C induces fibroblasts apoptosis and reduces epidural fibrosis by regulating miR-200b and its targeting of RhoE[J]. Eur J Pharmacol,2015,765:198-208. DOI: 10.1016/j.ejphar.2015.08.002.
[10]	谢红卫,陈霞,张海琼,等. 手术切除联合丝裂霉素C治疗耳廓增生性瘢痕的临床疗效[J]. 中南大学学报(医学版),2020,45(11):1368-1371. DOI: 10.11817/j.issn.1672-7347.2020.200388.
[11]	ZhengB, FangQQ, WangXF, et al. The effect of topical ramipril and losartan cream in inhibiting scar formation[J]. Biomed Pharmacother,2019,118:109394. DOI: 10.1016/j.biopha.2019.109394.
[12]	许宁,薛学义,郭树平,等. 钙通道阻滞剂维拉帕米对转化生长因子-β1诱导尿道瘢痕成纤维细胞α-平滑肌肌动蛋白和细胞外基质的作用[J]. 中华实验外科杂志,2013,30(9):1924-1926. DOI: 10.3760/cma.j.issn.1001-9030.2013.09.050.
[13]	ChoiJ, HanYN, RhaEY, et al. Verapamil-containing silicone gel reduces scar hypertrophy[J]. Int Wound J,2021,18(5):647-656. DOI: 10.1111/iwj.13566.
[14]	WangR,MaoY,ZhangZY,et al.Role of verapamil in preventing and treating hypertrophic scars and keloids[J].Int Wound J,2016,13(4):461-468.DOI: 10.1111/iwj.12455.
[15]	WangP, GuLS, BiHS, et al. Comparing the efficacy and safety of intralesional verapamil with intralesional triamcinolone acetonide in treatment of hypertrophic scars and keloids: a meta-analysis of randomized controlled trials[J]. Aesthet Surg J,2021,41(6):NP567-NP575. DOI: 10.1093/asj/sjaa357.
[16]	ZhaoP, SuiBD, LiuN, et al. Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application[J]. Aging Cell,2017,16(5):1083-1093. DOI: 10.1111/acel.12635.
[17]	ChoganF, MirmajidiT, RezayanAH, et al. Design, fabrication, and optimization of a dual function three-layer scaffold for controlled release of metformin hydrochloride to alleviate fibrosis and accelerate wound healing[J]. Acta Biomater,2020,113:144-163. DOI: 10.1016/j.actbio.2020.06.031.
[18]	WangJF, ChenH, ShankowskyHA, et al. Improved scar in postburn patients following interferon-alpha2b treatment is associated with decreased angiogenesis mediated by vascular endothelial cell growth factor[J]. J Interferon Cytokine Res,2008,28(7):423-434. DOI: 10.1089/jir.2007.0104.
[19]	孟凡伟,刘玉强,史本康,等.干扰素-α2b对尿道瘢痕成纤维细胞生物学的影响[J].山东大学学报(医学版),2011,49(12):92-95.
[20]	BiWR,XuGT,LvLX,et al.The ratio of transforming growth factor-β1/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis[J].Genet Mol Res,2014,13(1):1005-1014.DOI: 10.4238/2014.February.20.2.
[21]	QiuSS, DotorJ, HontanillaB. Effect of P144® (anti-TGF-β) in an "in vivo" human hypertrophic scar model in nude mice[J]. PLoS One,2015,10(12):e0144489. DOI: 10.1371/journal.pone.0144489.
[22]	KwakDH, BaeTH, KimWS, et al. Anti-vascular endothelial growth factor (bevacizumab) therapy reduces hypertrophic scar formation in a rabbit ear wounding model[J]. Arch Plast Surg,2016,43(6):491-497. DOI: 10.5999/aps.2016.43.6.491.
[23]	ShiJ, WuYT, GuoSY, et al. The efficacy of anti-VEGF antibody-modified liposomes loaded with paeonol in the prevention and treatment of hypertrophic scars[J]. Drug Dev Ind Pharm,2019,45(3):439-455. DOI: 10.1080/03639045.2018.1546315.
[24]	XieJL, BianHN, QiSH, et al. Basic fibroblast growth factor (bFGF) alleviates the scar of the rabbit ear model in wound healing[J]. Wound Repair Regen,2008,16(4):576-581. DOI: 10.1111/j.1524-475X.2008.00405.x.
[25]	PanSC, LeeCH, ChenCL, et al. Angiogenin attenuates scar formation in burn patients by reducing fibroblast proliferation and transforming growth factor β1 secretion[J]. Ann Plast Surg, 2018, 80(2S Suppl 1):S79-83. DOI: 10.1097/SAP.0000000000001306.
[26]	WangP,JiangLZ,XueB.Recombinant human endostatin reduces hypertrophic scar formation in rabbit ear model through down-regulation of VEGF and TIMP-1[J].Afr Health Sci,2016,16(2):542-553.DOI: 10.4314/ahs.v16i2.23.
[27]	GongYF, ZhangXM, YuJ, et al. Effect of recombinant human endostatin on hypertrophic scar fibroblast apoptosis in a rabbit ear model[J]. Biomed Pharmacother,2017,91:680-686. DOI: 10.1016/j.biopha.2017.04.116.
[28]	ChenBG, LiHC, XiaW. Imiquimod regulating Th1 and Th2 cell-related chemokines to inhibit scar hyperplasia[J]. Int Wound J,2019,16(6):1281-1288. DOI: 10.1111/iwj.13183.
[29]	MenezesMCS, BuzelinM, NunesCB, et al. Tacrolimus action pathways in an ointment base for hypertrophic scar prevention in a rabbit ear model[J]. An Bras Dermatol,2021,96(4):429-435. DOI: 10.1016/j.abd.2020.08.019.
[30]	LiHM, PengQ, GuoYS, et al. Preparation and in vitro and in vivo study of asiaticoside-loaded nanoemulsions and nanoemulsions-based gels for transdermal delivery[J]. Int J Nanomedicine,2020,15:3123-3136. DOI: 10.2147/IJN.S241923.
[31]	SongJY, TruongDV, YangBS. Quercetin shows the pharmacological activity to simultaneously downregulate the inflammatory and fibrotic responses to tissue injury in association with its ability to target multi-kinases[J]. Pharmacology,2018,102(3/4):142-153. DOI: 10.1159/000490417.
[32]	WangF, LiXX, WangXY, et al. Efficacy of topical silicone gel in scar management: a systematic review and meta-analysis of randomised controlled trials[J]. Int Wound J, 2020, 17(3):765-773. DOI: 10.1111/iwj.13337.
[33]	KimSH, LeeSJ, LeeJW, et al. Clinical trial to evaluate the efficacy of botulinum toxin type A injection for reducing scars in patients with forehead laceration: a double-blinded, randomized controlled study[J]. Medicine (Baltimore),2019,98(34):e16952. DOI: 10.1097/MD.0000000000016952.
[34]	BiML, SunPF, LiDY, et al. Intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: a systematic review and meta-analysis[J]. Med Sci Monit,2019,25:2950-2958. DOI: 10.12659/MSM.916305.
[35]	RiccioM, MarchesiniA, SenesiL, et al. Managing pathologic scars by injecting auto-cross-linked hyaluronic acid: a preliminary prospective clinical study[J]. Aesthetic Plast Surg,2019,43(2):480-489. DOI: 10.1007/s00266-018-01303-3.
[36]	HuCH, TsengYW, LeeCW, et al. Combination of mesenchymal stem cell-conditioned medium and botulinum toxin type A for treating human hypertrophic scars[J]. J Plast Reconstr Aesthet Surg,2020,73(3):516-527. DOI: 10.1016/j.bjps.2019.07.010.
[37]	XieF, TengL, XuJJ, et al. Adipose-derived mesenchymal stem cells inhibit cell proliferation and migration and suppress extracellular matrix synthesis in hypertrophic-scar and keloid fibroblasts[J]. Exp Ther Med,2021,21(2):139. DOI: 10.3892/etm.2020.9571.
[38]	RenY,DengCL,WanWD,et al.Suppressive effects of induced pluripotent stem cell-conditioned medium on in vitro hypertrophic scarring fibroblast activation[J].Mol Med Rep,2015,11(4):2471-2476.DOI: 10.3892/mmr.2014.3115.
[39]	NiJ, LiuXJ, YinYH, et al. Exosomes derived from TIMP2-modified human umbilical cord mesenchymal stem cells enhance the repair effect in rat model with myocardial infarction possibly by the Akt/Sfrp2 pathway[J]. Oxid Med Cell Longev,2019,2019:1958941. DOI: 10.1155/2019/1958941.
[40]	ZhaoB, ZhangYJ, HanSC, et al. Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation[J]. J Mol Histol,2017,48(2):121-132. DOI: 10.1007/s10735-017-9711-x.
[41]	辛增桃,田朦,靳林昊,等. 纳米脂肪联合PRP注射治疗增生性瘢痕[J]. 中国美容医学,2020,29(10):69-72.
[42]	DaiZZ, LouXZ, ShenT, et al. Combination of ablative fractional carbon dioxide laser and platelet-rich plasma treatment to improve hypertrophic scars: a retrospective clinical observational study[J/OL]. Burns Trauma,2021,9:tkab016[2021-11-18]. https://pubmed.ncbi.nlm.nih.gov/34337088/.DOI: 10.1093/burnst/tkab016.
[43]	WengWZ, HeSS, SongHY, et al. Aligned carbon nanotubes reduce hypertrophic scar via regulating cell behavior[J]. ACS Nano,2018,12(8):7601-7612. DOI: 10.1021/acsnano.7b07439.